咪唑斯汀治疗荨麻疹前后患者血浆中组胺含量的变化及其意义

Alteration of Plasma Histamine in Patients with Urticaria Before and After Treatment with Mizolastine and Its Clinical Significance

目的 探讨组胺在荨麻疹发病中的意义及咪唑斯汀在治疗荨麻疹中的抗组胺作用。方法 采用酶免疫法测定 45例荨麻疹患者在应用咪唑斯汀治疗前后血浆中的组胺含量。结果 2 4例急性荨麻疹和 2 1例慢性荨麻疹患者血浆中组胺水平较正常对照组升高 ,差异有显著性 ;症状缓解后组胺含量下降 ,与对照组间差异无显著性。急、慢性荨麻疹组胺含量在治疗前后差异均有显著性。结论 组胺是参与荨麻疹发病的主要介质之一 ,结合治疗观察有利于进一步了解荨麻疹的发病机理并指导临床用药。

Objective To explore the role of histamine in the pathogenesis of urticaria and the antihistamine activity of mizolastine in treating urticaria. Methods Detected plasma level of histamine of 45 patients with urticaria by enzyme immunoassay method before and after treatment with mizolastine. Results The results showed that plasma level of histamine of 24 patients with acute uricaria and 21 patients with chronic urticaria was significantly higher than that of normal controls. When the urticaria lesions disappeared or improved after treatment with mizolastine, plasma level of histamine of urticaria patients decreased. There was no statistical difference than that of normal controls. There was significant difference in the plasma level of histamine of urticaria patients before and after treatment with mizolastine. Conclusion It suggests that histamine plays an important role in the pathogenesis of urticaria, it is beneficial to understand further the pathogenesis of urticaria when co-observed with therapy and instruct clinical medication.